GO:2000818 negative regulation of myoblast proliferation: Myogenesis Control, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:2000818 describes any process that stops, prevents or reduces the frequency, rate or extent of myoblast proliferation, a critical checkpoint in skeletal muscle formation and repair.
• Myostatin (MSTN) is a canonical negative regulator that inhibits myoblast proliferation through SMAD2/3-dependent signaling, and its expression is itself auto-regulated by Smad3 and microRNA-27.
• TGFβ1 signaling, when epigenetically activated by targeted demethylation, promotes myoblast proliferation via SMAD2, revealing context-dependent control of this GO term.
• Fbxw7β acts as an E3 ubiquitin ligase that negatively regulates primary myoblast differentiation, proliferation and migration, linking proteostasis to this process.
• TBC1D1 functions as a negative regulator of satellite cells for muscle regeneration, directly impacting the proliferative capacity of muscle stem cells.
• Dysregulation of negative regulation of myoblast proliferation contributes to neuromuscular disorders, muscle wasting and impaired regeneration, making it a therapeutic target.
Description
Skeletal muscle is a highly regenerative tissue whose maintenance depends on the precise control of myoblast proliferation. Myoblasts are muscle precursor cells that must divide to expand the progenitor pool before differentiating and fusing into multinucleated myotubes. The Gene Ontology term GO:2000818, negative regulation of myoblast proliferation, captures the biological processes that stop, prevent or reduce the frequency, rate or extent of myoblast proliferation. This term is essential for understanding how muscle growth is restrained and how regeneration is balanced. Disruption of these brakes can lead to excessive or insufficient myoblast expansion, contributing to neuromuscular disorders and impaired muscle repair. Mechanistically, negative regulation of myoblast proliferation is enforced by secreted factors, intracellular signaling cascades and ubiquitin-dependent degradation. Myostatin, a member of the TGFβ superfamily, is a well-established negative regulator that inhibits myoblast proliferation. Its activity is fine-tuned by Smad3 and microRNA-27, which mediate negative auto-regulation of myostatin expression. In addition, TGFβ1 signaling can either promote or inhibit proliferation depending on epigenetic context, as targeted demethylation of TGFβ1 mRNA promotes myoblast proliferation via SMAD2 activation. These examples illustrate that GO:2000818 is not a single pathway but a convergence point for multiple regulatory inputs. For researchers, GO:2000818 provides a framework to study muscle stem cell quiescence, activation and differentiation. The term is also relevant to regenerative medicine, cachexia and sarcopenia, where manipulating the negative regulators of myoblast proliferation could enhance muscle repair. Understanding the genes and mechanisms that execute this process is therefore a prerequisite for developing targeted CRISPR-based models and therapeutic strategies.
negative regulation of myoblast proliferation At A Glance
| GO ID | GO:2000818 |
|---|---|
| GO term | negative regulation of myoblast proliferation |
| Ontology | biological_process |
| Synonym | none |
| Major function | Restraining the division of myoblasts to balance muscle growth and regeneration |
| Definition | Any process that stops, prevents or reduces the frequency, rate or extent of myoblast proliferation. |
| Related processes | Myoblast differentiation, satellite cell activation, muscle regeneration, TGFβ/BMP signaling |
| Key regulators | MSTN, SMAD2/3, TGFβ1, Fbxw7β, TBC1D1, microRNA-27 |
| Disease relevance | Neuromuscular disorders, muscle wasting, impaired regeneration |
What Is GO:2000818?
GO:2000818, negative regulation of myoblast proliferation, is defined as any process that stops, prevents or reduces the frequency, rate or extent of myoblast proliferation. In other words, it encompasses all molecular and cellular events that put the brakes on the division of muscle precursor cells, ensuring that myoblast expansion is tightly controlled during muscle development and regeneration.
Why Is negative regulation of myoblast proliferation Important in Cell Biology?
Negative regulation of myoblast proliferation is a fundamental checkpoint in skeletal muscle biology. Without it, myoblasts would undergo unchecked expansion, depleting the satellite cell pool and preventing proper differentiation and muscle repair. This GO term is important because it integrates signals from growth factors, ubiquitin ligases and epigenetic modifiers, and its dysregulation is linked to neuromuscular disorders and regenerative failure. Understanding how this process is controlled can inform therapeutic strategies for muscle-wasting conditions and for optimizing muscle regeneration after injury.
• Controls the balance between myoblast expansion and differentiation during muscle development.
• Prevents premature depletion of satellite cells, which are essential for lifelong muscle regeneration.
• Myostatin, a classic negative regulator, inhibits myoblast proliferation and its loss causes muscle hypertrophy.
• Smad3 and microRNA-27 mediate negative auto-regulation of myostatin, adding layered control.
• TGFβ1 signaling can be epigenetically modulated to either promote or inhibit myoblast proliferation.
• Fbxw7β negatively regulates myoblast differentiation, proliferation and migration, linking proteolysis to this process.
• TBC1D1 acts as a negative regulator of satellite cells, affecting muscle regeneration capacity.
• Dysregulation of this process contributes to neuromuscular disorders and satellite cell-opathies.
• Provides targets for CRISPR-based screens to identify novel regulators of muscle growth.
• Relevant to livestock muscle yield, as FGFR1 promoter hypomethylation facilitates myoblast proliferation.
What Happens During negative regulation of myoblast proliferation?
Extracellular inhibitory signals
In simple terms: Outside the cell, molecules like myostatin tell myoblasts to stop dividing.
Negative regulation of myoblast proliferation often begins with secreted factors. Myostatin (MSTN), a TGFβ superfamily member, is a well-characterized negative regulator that inhibits myoblast proliferation. Its expression is auto-regulated by Smad3 and microRNA-27, forming a feedback loop that fine-tunes its inhibitory activity. TGFβ1 can also influence myoblast proliferation, and targeted demethylation of TGFβ1 mRNA promotes proliferation via SMAD2, indicating that the epigenetic state of ligands modulates this process. These extracellular cues set the stage for intracellular signaling that enforces the proliferation brake.
Intracellular SMAD signaling
In simple terms: Inside the cell, SMAD proteins carry the stop signal from the surface to the nucleus.
Once myostatin or TGFβ1 binds to its receptors, SMAD2 and SMAD3 are phosphorylated and translocate to the nucleus to regulate gene expression. Smad3 directly mediates negative auto-regulation of myostatin, while SMAD2 activation downstream of TGFβ1 can either promote or inhibit proliferation depending on context. This duality highlights that the outcome for myoblast proliferation depends on the integration of multiple SMAD-dependent inputs. The balance between these signals determines whether myoblasts continue to divide or exit the cell cycle.
Ubiquitin-proteasome control
In simple terms: A cellular disposal system tags specific proteins for destruction to stop myoblast division.
The E3 ubiquitin ligase Fbxw7β negatively regulates primary myoblast differentiation, proliferation and migration. By targeting key proteins for ubiquitination and proteasomal degradation, Fbxw7β can remove factors that promote proliferation or drive differentiation. This adds a post-translational layer to GO:2000818, ensuring that myoblast proliferation is restrained not only by transcriptional changes but also by controlled protein turnover. The involvement of Fbxw7β links this GO term to broader proteostasis networks in muscle cells.
Satellite cell quiescence and regeneration
In simple terms: Muscle stem cells must be kept quiet until needed, and negative regulators maintain this quiet state.
Satellite cells are the resident muscle stem cells that support regeneration. TBC1D1 functions as a negative regulator of satellite cells for muscle regeneration, meaning that its activity restrains their proliferative expansion. This is critical because excessive or premature activation can exhaust the satellite cell pool. Negative regulation of myoblast proliferation therefore protects the regenerative capacity of muscle by maintaining a reserve of stem cells. Dysfunction in this process is implicated in neuromuscular disorders and satellite cell-opathies.
Epigenetic and transcriptional modulation
In simple terms: Chemical tags on DNA and RNA can dial the stop signal up or down.
Epigenetic mechanisms modulate negative regulation of myoblast proliferation. For example, hypomethylation of the FGFR1 promoter facilitates myoblast proliferation, indicating that DNA methylation status influences proliferative capacity. Conversely, targeted demethylation of TGFβ1 mRNA promotes myoblast proliferation via SMAD2, showing that RNA methylation can also impact this process. These findings demonstrate that the negative regulation of myoblast proliferation is not static but dynamically regulated by epigenetic marks that respond to developmental and environmental cues.
Key Genes Involved in GO:2000818 negative regulation of myoblast proliferation
The following genes and proteins have been experimentally linked to the negative regulation of myoblast proliferation, based on the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| MSTN | Secreted TGFβ family ligand that inhibits myoblast proliferation | Canonical negative regulator; loss causes muscle hypertrophy |
| SMAD2 | Intracellular signal transducer downstream of TGFβ1 | Mediates TGFβ1-induced effects on myoblast proliferation |
| SMAD3 | Intracellular signal transducer mediating myostatin auto-regulation | Links myostatin feedback to microRNA-27 |
| TGFβ1 | Secreted ligand that can promote or inhibit myoblast proliferation | Epigenetic demethylation promotes proliferation via SMAD2 |
| Fbxw7β | E3 ubiquitin ligase | Negatively regulates myoblast differentiation, proliferation and migration |
| TBC1D1 | Negative regulator of satellite cells | Restrains satellite cell expansion for muscle regeneration |
| FGFR1 | Receptor tyrosine kinase | Promoter hypomethylation facilitates myoblast proliferation |
| MIR27 | MicroRNA-27 | Mediates negative auto-regulation of myostatin with Smad3 |
| RPS27L | Ribosomal protein that enhances myogenesis | Targets IGF1 via liquid-liquid phase separation |
| IGF1 | Growth factor promoting myogenesis | Downstream target of RPS27L in myogenesis |
| PAX7 | Satellite cell marker and regulator | Contextual role in satellite cell function |
| MYOD1 | Myogenic determination factor | Coordinates differentiation and proliferation exit |
| MYF5 | Myogenic regulatory factor | Involved in myoblast commitment |
| MEF2C | Transcription factor | Regulates muscle differentiation genes |
| CDKN1A | Cyclin-dependent kinase inhibitor | Cell cycle brake in myoblasts |
| CDKN1B | Cyclin-dependent kinase inhibitor | Contributes to cell cycle exit |
| MURF1 | E3 ubiquitin ligase | Muscle atrophy-related proteolysis |
How Is negative regulation of myoblast proliferation Regulated?
Negative regulation of myoblast proliferation is controlled by a network of secreted ligands, intracellular SMAD signaling, ubiquitin ligases and epigenetic modifiers. Myostatin is a central negative regulator whose expression is auto-regulated by Smad3 and microRNA-27. TGFβ1 signaling can be modulated by targeted demethylation of its mRNA, which promotes myoblast proliferation via SMAD2, illustrating context-dependent regulation. Fbxw7β provides post-translational control through ubiquitination. TBC1D1 negatively regulates satellite cells, affecting the regenerative response. Additionally, promoter hypomethylation of FGFR1 facilitates myoblast proliferation, showing that epigenetic states influence the balance. Together, these layers ensure that myoblast proliferation is restrained when appropriate.
negative regulation of myoblast proliferation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| MSTN | Muscle hypertrophy, cachexia | MSTN knockout mouse or CRISPR KO in C2C12 myoblasts |
| TBC1D1 | Impaired muscle regeneration | Satellite cell-specific TBC1D1 knockout mouse |
| Fbxw7β | Myoblast dysfunction | Fbxw7β overexpression or knockout in primary myoblasts |
| TGFβ1 | Fibrosis, muscle wasting | TGFβ1 demethylation models in myoblasts |
| FGFR1 | Muscle growth variation | FGFR1 promoter hypomethylation in bovine myoblasts |
Neuromuscular disorders and satellite cell-opathies
Dysfunction in muscle satellite cells, which are the source of myoblasts, is implicated in a range of neuromuscular disorders collectively termed satellite cell-opathies. Impaired negative regulation of myoblast proliferation can lead to premature satellite cell activation and exhaustion, contributing to disease progression. Understanding GO:2000818 is therefore relevant for developing therapies that preserve muscle regenerative capacity.
Muscle wasting and impaired regeneration
Conditions characterized by muscle wasting, such as cachexia and sarcopenia, often involve an imbalance between myoblast proliferation and differentiation. TBC1D1 acts as a negative regulator of satellite cells for muscle regeneration, and its dysregulation may impair the regenerative response. Modulating negative regulators of myoblast proliferation could potentially enhance muscle repair in these conditions.
Myostatin-related muscle hypertrophy
Myostatin is a negative regulator of muscle growth that functions by inhibiting myoblast proliferation. Loss-of-function mutations in MSTN lead to excessive muscle mass in animals and humans. This highlights the therapeutic potential of targeting the myostatin pathway to promote muscle growth, but also underscores the need for precise control to avoid adverse effects.
From negative regulation of myoblast proliferation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a candidate gene enhance myoblast proliferation? | CRISPR knockout in C2C12 or primary myoblasts |
| Does a specific point mutation in MSTN affect its inhibitory function? | CRISPR point mutation knock-in in myoblasts |
| Can a tagged version of Fbxw7β reveal its interactome? | Knock-in of epitope tag at endogenous locus |
| Does overexpression of TBC1D1 inhibit satellite cell activation? | Lentiviral overexpression in satellite cells |
| What is the role of SMAD2 phosphorylation in TGFβ1-mediated proliferation? | Point mutation of SMAD2 phosphorylation sites |
| Can epigenetic editing of TGFβ1 mRNA alter myoblast proliferation? | Targeted demethylation using CRISPR-dCas9-TET1 |
How to Study the negative regulation of myoblast proliferation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Global gene expression changes | Identify pathways altered by TBC1D1 knockout |
| EdU incorporation | DNA synthesis as a proxy for proliferation | Measure myoblast proliferation after gene manipulation |
| Immunoprecipitation-MS | Protein-protein interactions | Discover Fbxw7β substrates |
| Phosphoproteomics | Signaling pathway activation | Map SMAD2/3 phosphorylation after TGFβ1 treatment |
| Bisulfite sequencing | DNA methylation status | Assess FGFR1 promoter methylation |
| MeRIP-seq | m6A RNA methylation | Detect TGFβ1 mRNA demethylation |
| Live-cell imaging | Real-time proliferation dynamics | Track myoblast division in culture |
Transcriptomic profiling
RNA sequencing (RNA-seq) can be used to identify global changes in gene expression when negative regulators of myoblast proliferation are manipulated. For example, comparing wild-type and TBC1D1 knockout satellite cells can reveal pathways that drive proliferation. Similarly, RNA-seq of myoblasts treated with myostatin or TGFβ1 can uncover downstream targets of SMAD signaling.
Proteomic and interactome analysis
Proteomics approaches, such as immunoprecipitation coupled to mass spectrometry, can identify proteins that interact with negative regulators like Fbxw7β or TBC1D1. This helps define the molecular complexes that execute the proliferation brake. Phosphoproteomics can also map signaling events downstream of TGFβ1 and myostatin.
Imaging and proliferation assays
Live-cell imaging and EdU/BrdU incorporation assays are standard for measuring myoblast proliferation rates. These methods can be applied to cells with CRISPR-mediated knockout or overexpression of candidate genes to directly test their role in GO:2000818. Immunofluorescence for markers like Ki67 or phospho-histone H3 provides spatial information on proliferating cells.
Epigenetic and epitranscriptomic analysis
Given the role of DNA and RNA methylation in regulating myoblast proliferation, methods such as bisulfite sequencing and MeRIP-seq can assess promoter methylation and m6A modifications, respectively. These techniques help link epigenetic changes to the expression of negative regulators and their downstream effects on proliferation.
How CRISPR Can Be Used to Study GO:2000818 negative regulation of myoblast proliferation
Knockout
CRISPR knockout is used to delete candidate negative regulators of myoblast proliferation, such as MSTN, TBC1D1 or Fbxw7β, to assess whether their loss increases proliferation. This approach provides causal evidence for gene function in GO:2000818. Knockout models can be generated in C2C12 myoblasts or primary satellite cells for downstream proliferation assays.
Point Mutation
Point mutations can be introduced to dissect specific domains or phosphorylation sites. For example, mutating SMAD2 phosphorylation sites can test their requirement for TGFβ1-mediated effects on proliferation. Similarly, point mutations in MSTN can reveal residues critical for its inhibitory activity. These models offer fine-grained mechanistic insights.
Knock-in
Knock-in of epitope tags or fluorescent reporters at endogenous loci allows visualization and purification of negative regulators like Fbxw7β or TBC1D1. This enables interactome studies and live-cell imaging without overexpression artifacts. Knock-in of disease-associated mutations can also model human conditions.
Overexpression
Overexpression of candidate genes, such as TBC1D1 or Fbxw7β, can test whether increased levels are sufficient to inhibit myoblast proliferation. This is particularly useful for validating negative regulators identified in screens. Overexpression can be achieved via lentiviral transduction or CRISPR activation (CRISPRa).
How EDITGENE Supports negative regulation of myoblast proliferation Research
Researchers studying negative regulation of myoblast proliferation-related genes often need to determine whether a candidate gene is causally involved in restraining myoblast division, and to dissect the precise molecular mechanisms. EDITGENE provides a comprehensive suite of CRISPR services to generate knockout, point-mutation, knock-in and overexpression cell models, as well as library screening and bioinformatics support, enabling rigorous investigation of GO:2000818.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of myoblast proliferation research.
Frequently Asked Questions About negative regulation of myoblast proliferation
What is GO:2000818?
GO:2000818 is the Gene Ontology term for negative regulation of myoblast proliferation, defined as any process that stops, prevents or reduces the frequency, rate or extent of myoblast proliferation.
What genes are involved in negative regulation of myoblast proliferation?
Key genes include MSTN, SMAD2, SMAD3, TGFβ1, Fbxw7β, TBC1D1, FGFR1 and microRNA-27, among others.
How does myostatin inhibit myoblast proliferation?
Myostatin, a TGFβ family ligand, binds to receptors and activates SMAD2/3 signaling, which leads to inhibition of myoblast proliferation.
What is the role of Fbxw7β in myoblast proliferation?
Fbxw7β is an E3 ubiquitin ligase that negatively regulates primary myoblast differentiation, proliferation and migration, likely by targeting proteins for degradation.
How is negative regulation of myoblast proliferation studied?
Researchers use CRISPR knockout, overexpression, RNA-seq, proteomics, imaging and proliferation assays to study this process.
What diseases are associated with dysregulated myoblast proliferation?
Neuromuscular disorders, satellite cell-opathies, muscle wasting and cachexia have been linked to defects in myoblast proliferation control.
Can CRISPR be used to study negative regulation of myoblast proliferation?
Yes, CRISPR knockout, point mutation, knock-in and overexpression models are powerful tools to dissect gene function in this process.
What is the role of TGFβ1 in myoblast proliferation?
TGFβ1 can either promote or inhibit myoblast proliferation depending on context; targeted demethylation of TGFβ1 mRNA promotes proliferation via SMAD2.
How does TBC1D1 affect muscle regeneration?
TBC1D1 functions as a negative regulator of satellite cells, and its loss enhances satellite cell expansion and muscle regeneration.
What are the key signaling pathways in negative regulation of myoblast proliferation?
The TGFβ/SMAD, myostatin, and ubiquitin-proteasome pathways are central, with additional input from epigenetic modifiers.
Conclusion
GO:2000818, negative regulation of myoblast proliferation, is a critical biological process that ensures proper muscle development and regeneration by restraining myoblast division. The interplay of myostatin, SMAD signaling, ubiquitin ligases and epigenetic modifiers provides multiple layers of control. Dysregulation of this process contributes to neuromuscular disorders and muscle wasting, making it an attractive target for therapeutic intervention. Continued research using CRISPR-based models and multi-omics approaches will further elucidate the mechanisms and identify new druggable nodes.
References
- 1. Ganassi M et al.. 2022. Involvement of muscle satellite cell dysfunction in neuromuscular disorders: Expanding the portfolio of satellite cell-opathies.. Eur J Transl Myol 32(1) PMID: 35302338
- 2. Cheng J et al.. 2020. Transcriptional regulation of the bovine FGFR1 gene facilitates myoblast proliferation under hypomethylation of the promoter.. J Cell Physiol 235(11):8667-8678 PMID: 32324257
- 3. Shin K et al.. 2017. Fbxw7β, E3 ubiquitin ligase, negative regulation of primary myoblast differentiation, proliferation and migration.. Anim Sci J 88(4):712-719 PMID: 27594513
- 4. Deng K et al.. 2023. Targeted Demethylation of the TGFβ1 mRNA Promotes Myoblast Proliferation via Activating the SMAD2 Signaling Pathway.. Cells 12(7) PMID: 37048078
- 5. Thomas M et al.. 2000. Myostatin, a negative regulator of muscle growth, functions by inhibiting myoblast proliferation.. J Biol Chem 275(51):40235-43 PMID: 10976104
- 6. Yang X et al.. 2025. TBC1D1 functions as a negative regulator of satellite cells for muscle regeneration.. Nat Commun 16(1):10091 PMID: 41253787
- 7. McFarlane C et al.. 2014. Negative auto-regulation of myostatin expression is mediated by Smad3 and microRNA-27.. PLoS One 9(1):e87687 PMID: 24498167
- 8. Liu X et al.. 2025. RPS27L Enhances Myogenesis and Muscle Mass by Targeting IGF1 Through Liquid-Liquid Phase Separation.. Adv Sci (Weinh) 12(44):e12354 PMID: 40886325
